ARTICLE | Finance
Fungal flexibility
How antifungal play Amplyx plans to deploy series C
August 4, 2017 11:54 PM UTC
Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001.
On Aug. 2, the biotech raised $67 million in an oversubscribed series C round that was led by Sofinnova Ventures, with participation from new investors Arix Bioscience, Lundbeckfonden Ventures and Pappas Capital...
BCIQ Company Profiles